April 11, 2022 - Iris Pharma obtains renewal of its accreditation for the research tax credit (CIR) by the French Ministry Responsible for Research, insuring its potential to do research and development, product innovation or work to develop a new range of products.
Its recognition procures a significant financial benefit – covering a 30% rate of eligible R&D expenses for French based firms wishing to pursue their R & D work in ophthalmology with Iris Pharma.
Iris Pharma can proudly point to the fact that it have been accredited this way since 2004, a token of the lasting performance of its activity.
